APA (7th ed.) Citation

BF, B., NC, H., P, I., M, W., TE, H., & JE, V. (2018). Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061. The Journal of pharmacology and experimental therapeutics, 365(2), 301. https://doi.org/10.1124/jpet.117.246272

Chicago Style (17th ed.) Citation

BF, Burkey, Hoglen NC, Inskeep P, Wyman M, Hughes TE, and Vath JE. "Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061." The Journal of Pharmacology and Experimental Therapeutics 365, no. 2 (2018): 301. https://doi.org/10.1124/jpet.117.246272.

MLA (9th ed.) Citation

BF, Burkey, et al. "Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061." The Journal of Pharmacology and Experimental Therapeutics, vol. 365, no. 2, 2018, p. 301, https://doi.org/10.1124/jpet.117.246272.